MWTX-003 Wins FDA Fast Track Designation for Polycythemia Vera

The FDA has granted fast track designation to the investigational, anti-TMPRSS6 monoclonal antibody, MWTX-003 (DISC-3405), for use in the treatment of patients with polycythemia vera, according to an announcement from Disc Medicine, Inc.1

Related Keywords

,John Quisel ,Disc Medicine Inc ,European Commission ,European Medicines Agency ,Medicinal Products ,Human Use ,Disc Medicine ,Mabwell Therapeutics ,Fema ,Chmp ,Committee For Medicinal Products Human Use ,